Mustafa Al Izzi
Department of Rheumatology, Mediclinic Welcare Hospital, UAEFulltext PDF
The inflammatory myopathies are a group of disorders sharing the common feature of immunemediated muscle disorder. The most common of these disorders include; Dermatomyositis (DM), overlap syndromes (with another systemic rheumatic disease), Inclusion Body Myositis (IBM) which is usually refractory to conventional therapy, Immune-Mediated Necrotizing Myopathy (IMNM) and Polymyositis (PM). Other subtypes of inflammatory myopathy include eosinophilic myositis and granulomatous myositis.Polymyositis treatment is usually prolonged and includes a battery of immunomodulating medications mainly systemic steroids, methotrexate and azathioprine frequently used in combination but many cases prove resistant necessitating more potent therapeutic options such as rituximab, Intravenous Immunoglobulin (IVIG), mycophenolate mofetil, cyclosporine, tacrolimus and cyclophosphamide, however the outcome of such therapies can still be unsatisfactory.
Polymyositis (PM); Dermatomyositis (DM); Janus kinase (JAK)
Al Izzi M. Successful Treatment of a Refractory Polymyositis Patient with Tofacitinib. Am J Arthritis. 2020;4(1):1017..